Found 4 matching trials
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
PHASE1The standard or usual treatment for this disease is to undergo chemotherapy...
Status
Active Not Recruiting
Location
BCCA - Vancouver Cancer Centre
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
PHASE2This study is being done to answer the following question: Can testing brea...
Location
Arthur J.E. Child Comprehensive Cancer Centre
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
PHASE1The purpose of this study is to test the safety of an investigational drug ...
Status
Active Not Recruiting
Location
The Ohio State University Comprehensive Cancer Center
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
PHASE1This is a phase 1 study of investigational agent CFI-402257 in patients wit...